Because Abraxis Bioscience, a subsidiary of Celgene, didn’t fix the problem of multiple media fill failures along the aseptic processing line at its biologics plant, the FDA hit the Phoenix, Ariz., company with a warning letter.
Source: Drug Industry Daily